Ezra Headshot - Horizontal.jpg


New York, New York

T: 917.451.2092

E: eangrist@altaviewadvisors.com


Princeton University, M.A. Politics (Quantitative Methods Concentration)

Rutgers University, M.B.A. Finance

Oberlin College, B.A. Economics



Ezra Angrist; Harry Curtis, III, CFA, ASA; Daniel Kerrigan, CFA. “Regression Analysis and Discounts for Lack of Marketability”. Business Valuation Review. Volume 30, Issue 1. Spring 2011.

Ezra Angrist is a Director of AltaView and is located in the firm’s New York office. He has more than 10 years of experience advising on valuation matters for businesses across a diverse range of industries, sizes, capital structures, and stages of development. Ezra also has extensive experience working with life science companies. He has nearly 15 years’ experience working at a life science-focused investment bank and previously served as CFO of a life science start up for more than five years.

Ezra has prepared valuation analyses and reports for attorneys, accountants, shareholders, boards of directors, and company management teams.

In addition, Ezra has expertise in the following areas:

  • Privately owned companies across a wide range of industries  

  • Restricted securities (Rule 144, insider stock, blockage discounts)

  • Discounts for lack of control and lack of marketability

  • Pass-through entities (S Corp, LLC, LP)

  • Early-stage companies

​Prior to joining AltaView, Ezra was a Vice President at Walter Greenblatt and Associates, LLC, a boutique life science-focused investment bank, where he assisted early-stage companies in raising capital. He was also Chief Compliance Officer and Financial and Operations Principal responsible for ensuring the firm’s compliance with applicable FINRA and SEC rules and regulations and the timely filing of required financial reports. Concurrently with his position at Walter Greenblatt and Associates, Ezra was Chief Financial Officer of Illuminare Biotechnologies, Inc., an early-stage life science company developing a nerve visualization agent designed to enable surgeons to better see nerves during surgery and improve clinical outcomes. Illuminare is a joint venture between Walter Greenblatt & Associates, LLC, General Electric, and Memorial Sloan Kettering Cancer Center.